The order covers a new oncology program focused on cancer cell-cycle regulation. Samples will be analyzed with Biovica’s DiviTum TKa test at its CLIA-certified laboratory in San Diego, with results used to assess drug activity and changes in cell proliferation during treatment.

The study is expected to start in January 2027 and run for about 24 months, with revenue recognized as samples are analyzed. The first work order under the agreement, worth about USD 100,000, was announced in July.

“A second order from the same customer, for a new program, is the pattern we want to see in Pharma Services,” says Theis Kipling, CEO of Biovica.